Novavax (NVAX) Stock Forecast for 2024–2028. Sell or Buy Prediction

Maximizing Profits: When is the Right Time to Sell Your Business?

April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?

Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
Improve Your Financial Status: A How-To Guide

April 12, 2024 Improve Your Financial Status: A How-To Guide

Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
How ZIM Integrated Container Tracking is Revolutionizing Global Trade

April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade

Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
6 Best Growth Stocks To Buy Now According to Metatrader 5

March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5

One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…

Novavax (NVAX) Stock Forecast for 2024–2028. Sell or Buy?

Updated: May 29, 2024 (13:26)

Sector: Healthcare

The share price of Novavax, Inc. (NVAX) now

Latest session on the 28th of May for
Novavax, Inc. is positive
Trading Volume: 19115523
Open: 15.28 /  High: 15.7 /  Low: 13.5
What analysts predict: $21.6
52-week High/Low: $17.4 / $3.532

50/200 Day Moving Average: $6.53 / $6.14

This figure corresponds to the Average Price over the previous 50/200 days. For Novavax stocks, the 50-day moving average is the support level today.

For Novavax stocks, the 200-day moving average is the support level today.

Are you interested in Novavax, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Novavax stock price in 2024, 2025, 2026, 2027, 2028. How much will one Novavax share be worth in 2024 - 2028?

When should I take profit in Novavax stock? When should I record a loss on Novavax stock? What are analysts' forecasts for Novavax stock? What is the future of Novavax stock? We forecast Novavax stock performance using neural networks based on historical data on Novavax stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.

Novavax stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, 2027 and 2028) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Novavax shares. This happens once a day.

Historical and forecast chart of Novavax stock

The chart below shows the historical price of Novavax stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Novavax stock price can be found in the table below.

Long-term forecasts by years.

A Renaissance in NVAX Stock: The Sanofi Catalyst and Beyond

Trend: Strong Bullish
May 12, 2024

For investors and analysts tracking Novavax (NVAX), the horizon seems particularly vibrant, pulsing with a mix of challenges and breakthrough opportunities that can sway the NVAX stock price prediction in considerable ways. Central to these developments is the groundbreaking licensing agreement with pharmaceutical titan Sanofi, a strategic partnership poised to inject not only a significant upfront capital boost but also sustained revenue streams through royalties. This collaboration, potentially valued up to $1.2 billion, represents a seismic shift, securing Novavax a coveted spot on the global vaccine stage and fundamentally altering the NVAX stock forecast.

The Pillars of Prediction: Analyzing NVAX's Future Stock Trajectory

To adeptly navigate the Novavax narrative and make informed decisions regarding whether NVAX is a good stock to buy, analysts would do well to dissect the multifaceted aspects influencing its stock rate. Foremost is the Sanofi pact, a veritable game-changer that lends immediate credence and financial bulwark to Novavax. This development alone could serve as a lighthouse, guiding NVAX stock price target adjustments and investor sentiment. Coupled with the recent earnings surpassing EPS expectations, despite a revenue miss, and the strategic forward march in their vaccine pipeline, these elements collectively paint a picture of a company on the verge of a bullish break.

Yet, for a rounded NVAX stock buy or sell analysis, one cannot overlook the inherent challenges—the rigors of market competition, the intricacies of regulatory navigations, and the integration of innovative vaccine technologies into the broader market. These factors, while possibly casting shadows, can also offer the astute analyst a nuanced understanding of the NVAX landscape, enabling a sharper NVAX stock price prediction.

Descending in order of importance, the licensing agreement with Sanofi undoubtedly is the celestial event in the NVAX stock forecast galaxy. Not far behind, the company's financial stability and promising pipeline development cast significant rays of hope for those pondering if NVAX is a good stock to buy. Regulatory trials and market competition, while certainly crucial, somewhat dim in comparison but should not be ignored by any looking to make a buy or sell Novavax stock decision.

In essence, tapping into the most accurate foresight into NVAX's stock trajectory requires a balanced analysis, weighing the monumental partnership with Sanofi against the backdrop of financial, developmental, and market dynamics. These considerations are paramount for those looking to target the NVAX stock price with precision, offering a blueprint for navigating the promising yet unpredictable terrain of Novavax's stock future.

Review the original Analysis
About author

Riding the Wave: How Novavax's Strategic Pivot and Sanofi Alliance Could Surge NVAX Stock

Trend: Neutral
May 10, 2024

As industry analysts peer into the crystal ball to forecast NVAX stock rates, a few critical events and factors emerge as pivotal in shaping the trajectory of Novavax's stock in the near future. At the heart of this anticipation is Novavax's strategic partnership with pharmaceutical behemoth, Sanofi. This collaboration isn't just a lifeline; it's a potent catalyst that injects not only crucial financial support but also a dose of confidence among investors regarding Novavax's fiscal stability and future prospects.

Zooming into the Future: Key Drivers of NVAX Stock Predictions

Understanding the factors that will most influence the change of NVAX stocks rate is crucial for making the most accurate predictions. These include:

  • Financial support from the Sanofi collaboration: The equity investments, alongside upfront and milestone payments from Sanofi, signal a brighter financial forecast for Novavax. Analysts eyeing the NVAX stock forecast recognize this as a pivot point, potentially marking the commencement of an upward trajectory for NVAX stock prices.
  • Competition in the combination vaccine market: With the race to market combination COVID-19 and influenza vaccines heating up, the positioning of Novavax against giants like Pfizer and Moderna becomes a critical variable. An analyst pondering 'is NVAX a good stock to buy' will keenly evaluate Novavax’s strategies to compete and carve out market share in this arena.
  • Shift in strategy to licensing technology: Novavax's move to license its technology to Sanofi marks a strategic shift. For someone analyzing the NVAX stock price prediction, this approach suggests a reduction in development risk but also raises questions about long-term competitive positioning and royalty income potential.

For those pondering 'buy or sell Novavax stock,' these factors provide a compass by which to navigate. The NVAX stock forecast hinges on the successful execution of its partnership with Sanofi, its competitive acumen in the vaccine market, and the fruits of its licensing strategy. As these dynamics unfold, they offer analysts a blueprint to forecast the NVAX stock rates with a higher degree of certainty, speculating on whether NVAX stock is a buy or sell, and predicting future stock price targets.

Review the original Analysis
About author

Novavex, Inc. Together with its subsidiary Novavax AB, a late-stage biotechnology company, it discovers, develops and commercializes vaccines to prevent serious infectious diseases. The company’s leading vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate, which is in stage III clinical trials to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in phase III clinical trials for the treatment of seasonal influenza in the elderly. Its leading adjuvant is Matrix-M, which is used to enable the vaccine to enhance the amplitude of the immune response and qualitatively change it, and to allow the immune system to attack microorganisms, and also to allow immunization with much smaller doses of antigen. The company is also developing the RSV F vaccine for the elderly (60 years and older), which is in phase II clinical trials, as well as for healthy children aged six months to five years, who are in phase I clinical trials. In addition, it is developing candidate nanoparticle vaccines for clinical trials against the Ebola virus, which is in clinical trials stage I; and a combined respiratory vaccine to protect against influenza and RSV. In addition, the company is developing a COVID-19 vaccine against the pneumonia-like coronavirus, which is in the preclinical stage. Novavex, Inc. the company was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax daily forecast for a month

Date Target Pes. Opt. Vol., %
May 31 16.37 15.25 17.21 12.85
Jun 01 15.88 15.57 16.58 6.52
Jun 02 14.69 14.13 15.08 6.74
Jun 03 13.76 13.22 14.56 10.11
Jun 04 13.51 12.99 14.41 10.95
Jun 05 13.91 13.20 14.31 8.44
Jun 06 13.85 13.24 14.20 7.25
Jun 07 14.41 14.15 15.16 7.15
Jun 08 14.78 14.37 15.42 7.31
Jun 09 13.61 12.67 14.34 13.15
Jun 10 13.16 12.92 13.54 4.77
Jun 11 14.05 13.47 14.30 6.20
Jun 12 14.06 13.77 14.60 6.07
Jun 13 13.84 13.01 14.46 11.11
Jun 14 13.93 13.64 14.60 6.98
Jun 15 14.21 13.68 14.85 8.50
Jun 16 14.32 13.95 15.02 7.67
Jun 17 14.77 14.00 15.04 7.41
Jun 18 15.24 14.62 15.93 8.91
Jun 19 15.57 14.78 15.91 7.58
Jun 20 15.47 15.12 16.35 8.10
Jun 21 15.33 15.06 15.80 4.95
Jun 22 15.64 14.95 16.16 8.10
Jun 23 16.01 14.89 16.42 10.26
Jun 24 16.17 15.08 17.24 14.28
Jun 25 16.32 15.23 17.26 13.31
Jun 26 15.75 15.42 16.26 5.42
Jun 27 14.53 13.74 15.02 9.32
Jun 28 15.06 14.53 15.33 5.50
Jun 29 13.80 12.92 14.62 13.17

Novavax Daily Price Targets

Novavax Stock Forecast 05-31-2024.

Forecast target price for 05-31-2024: $16.37.
Positive dynamics for Novavax shares will prevail with possible volatility of 11.386%.
Pessimistic target level: 15.25
Optimistic target level: 17.21

Novavax Stock Forecast 06-01-2024.

Forecast target price for 06-01-2024: $15.88.
Negative dynamics for Novavax shares will prevail with possible volatility of 6.120%.
Pessimistic target level: 15.57
Optimistic target level: 16.58

Novavax Stock Forecast 06-02-2024.

Forecast target price for 06-02-2024: $14.69.
Negative dynamics for Novavax shares will prevail with possible volatility of 6.315%.
Pessimistic target level: 14.13
Optimistic target level: 15.08

Novavax Stock Forecast 06-03-2024.

Forecast target price for 06-03-2024: $13.76.
Negative dynamics for Novavax shares will prevail with possible volatility of 9.183%.
Pessimistic target level: 13.22
Optimistic target level: 14.56

Novavax Stock Forecast 06-04-2024.

Forecast target price for 06-04-2024: $13.51.
Negative dynamics for Novavax shares will prevail with possible volatility of 9.872%.
Pessimistic target level: 12.99
Optimistic target level: 14.41

Novavax Stock Forecast 06-05-2024.

Forecast target price for 06-05-2024: $13.91.
Positive dynamics for Novavax shares will prevail with possible volatility of 7.786%.
Pessimistic target level: 13.20
Optimistic target level: 14.31

NVAX (NVAX) Monthly Stock Prediction for 2024

Month Target Pes. Opt. Vol., %
Jun. 17.38 14.61 18.84 22.42
Jul. 20.82 18.57 23.19 19.93
Aug. 21.44 16.87 23.37 27.80
Sep. 20.80 18.80 23.29 19.29
Oct. 22.92 20.79 25.95 19.88
Nov. 22.51 17.44 25.55 31.72
Dec. 28.85 22.28 35.43 37.13

Novavax forecast for this year

Novavax Stock Prediction for Jun 2024

An uptrend is forecast for this month with an optimal target price of $17.3768. Pessimistic: $14.61. Optimistic: $18.84

Novavax Stock Prediction for Jul 2024

An uptrend is forecast for this month with an optimal target price of $20.8174. Pessimistic: $18.57. Optimistic: $23.19

Novavax Stock Prediction for Aug 2024

An uptrend is forecast for this month with an optimal target price of $21.4419. Pessimistic: $16.87. Optimistic: $23.37

Novavax Stock Prediction for Sep 2024

An downtrend is forecast for this month with an optimal target price of $20.7987. Pessimistic: $18.80. Optimistic: $23.29

Novavax Stock Prediction for Oct 2024

An uptrend is forecast for this month with an optimal target price of $22.9201. Pessimistic: $20.79. Optimistic: $25.95

Novavax Stock Prediction for Nov 2024

An downtrend is forecast for this month with an optimal target price of $22.5076. Pessimistic: $17.44. Optimistic: $25.55

Novavax Stock Prediction for Dec 2024

An uptrend is forecast for this month with an optimal target price of $28.8547. Pessimistic: $22.28. Optimistic: $35.43

Novavax (NVAX) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jan 28.42 21.69 32.60 33.48
Mar 29.96 27.53 35.26 21.92
Mar 28.70 24.91 33.00 24.52
Apr 28.70 23.19 33.52 30.82
May 23.10 20.61 25.18 18.17
Jun 27.61 22.56 32.74 31.11
Jul 35.48 29.94 43.03 30.42
Aug 43.78 36.95 49.16 24.84
Sep 47.59 44.02 57.15 22.98
Oct 57.01 45.55 67.27 32.29
Nov 67.27 56.77 71.71 20.83
Dec 64.04 50.98 69.42 26.57

Novavax (NVAX) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 63.85 52.16 77.06 32.31
Mar 71.51 56.71 84.59 32.97
Mar 67.86 62.16 76.62 18.87
Apr 66.84 60.83 82.69 26.43
May 67.04 55.78 74.49 25.11
Jun 58.40 54.37 63.30 14.11
Jul 70.83 57.45 81.88 29.84
Aug 88.90 70.23 96.10 26.92
Sep 92.63 79.85 101.52 21.35
Oct 106.53 87.35 121.55 28.13
Nov 79.04 70.74 90.42 21.77
Dec 58.17 54.68 69.52 21.34

Novavax (NVAX) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 62.89 51.00 73.07 30.21
Mar 67.23 58.96 75.49 21.91
Mar 72.47 67.69 78.56 13.84
Apr 65.73 50.15 77.96 35.67
May 71.65 59.18 81.10 27.03
Jun 75.73 65.96 88.00 25.04
Jul 90.50 78.01 107.87 27.68
Aug 101.36 79.16 108.96 27.35
Sep 115.34 108.42 125.38 13.52
Oct 112.58 105.48 125.41 15.89
Nov 118.65 110.47 147.13 24.92
Dec 108.33 92.73 114.83 19.25

Novavax (NVAX) Monthly Stock Prediction for 2028

Month Target Pes. Opt. Vol., %
Jan 95.01 83.89 117.81 28.79
Feb 89.31 68.14 102.97 33.82
Mar 108.06 83.42 129.78 35.72
Apr 117.79 106.83 131.21 18.58
May 139.69 120.84 171.54 29.56
Jun 150.59 133.87 165.05 18.89
Jul 128.91 110.34 159.46 30.80
Aug 147.85 128.78 169.15 23.86
Sep 142.53 125.86 153.65 18.09
Oct 139.11 120.75 166.65 27.55
Nov 146.21 120.33 154.98 22.36
Dec 166.82 155.31 188.34 17.54

Novavax information and performance

Novavax Address


Market Capitalization: 2 283 119 000 $

Market capitalization of the Novavax, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of NVAX shares in the company outstanding by the market price of one share.

EBITDA: -333 844 992 $

EBITDA of Novavax is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: N/A

Price/earnings to growth

DPS: None

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: None

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -3.05

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 0.159
Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 1.782

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 0.468

Enterprise Value (EV) /Revenue

EV To EBITDA: -0.534

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 147298000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Novavax (NVAX) stock dividend

Novavax last paid dividends on 01/01/1970. The next scheduled payment will be on 05/10/2019. The amount of dividends is $None per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.

Last Split Factor:

Last Split Date: 01/01/1970

Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.

For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.

Related stocks from Healthcare sector


All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.